CEO and Founder. Responsible for international-business development for 20 years in CEO/board positions in cancer detection focused companies. Led as a CEO the IPO of NorDiag, cancer diagnostics company at Oslo Stock Exchange (main list). BBA from the College of William & Mary, USA, and AMP from Oxford University, UK.

Dr. Wohlgemuth has years of experience leading healthcare innovation efforts in diagnostic testing, medical devices, virtual care, and digital health. Dr. Wohlgemuth served as a Chief Medical Officer, CSO, and SVP for Quest Diagnostics. He earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine,

Hans Gangeskar guides DeepX AI/IP development and U.S. market entry. Hans is co-founder and former CEO of Nurx, a US-based $300m telemedicine company, and is a computer science / mathematics graduate from Cambridge University, UK and holds a J.D. from George Washington University Law School.

Medical and life science-focused venture capital investor. Led companies through IPOs on the Oslo Stock exchange and on Nasdaq. Hans is a graduate from the Norwegian School of Economics and Business Administration. Hans is former Chairman of Mainz Biomed (Nasdaq: "MYNZ").

Dermatologist and vice chairman for medical dermatology at the department of dermatology at the Mayo Clinic, US. Dr. Swanson’s primary research area is on non-invasive imaging technologies to diagnose skin cancer. Board advisor and lead author on several DeepX Health publications. MD university of Minnesota medical school. BA Saint Johns University, USA.

CFO with extensive business financial management, business leadership, and operating experience in companies including a fintech startup (United Income acquired by Capital One), financial services (FINCA), and more than 10 years of audit advisory experience from PwC, USA. MBA in finance from Government Academy of Economy, Moscow, Russia.

Former Head of Product at uBiome Inc., a microbiome diagnostics company, and research fellow at the Berkeley Institute for Data Science. Dr. Kraal received his PhD from UCSF, during which he was also involved with multiple life-sciences start-ups. He also attended Harvard Medical School, Osaka University, Utrecht University, and the University of Groningen. In addition to his PhD, he holds a MSc. in Biomedical Sciences, a BSc. in Molecular Biology and a BA in Theoretical Philosophy focused on AI.

General Manager at ScreenCancer and European operational and systems responsibility for the group. 20 years in leadership positions in insurance and customer centric organizations. MBA from Oslo Business School and attended Harvard Business School for Building & Leading Customer-Centric Organizations.

Extensive experience in product innovation consulting and healthcare. Additionally, a background in product and operations within the behavioral health sector. Holds a BSc in Systems Engineering and Financial Engineering from Washington University in St. Louis.

Dr. Mina is a physician-scientist, former professor at Harvard Medical School and executive leader with a focus at the intersection of biotechnology and data science, AI, healthcare product development, and regulation.

Andre Esteva is a leading researcher and entrepreneur in medical artificial intelligence, and CEO of ArteraAI. Andre was previously head of Medical AI at Salesforce. He has a PhD in AI from Stanford and was the lead author of a landmark publication in Nature on the use of AI for skin cancer detection.

Former SVP Healthcare Services at Walgreens Boots Alliance. Founder of Option 5 Health. Member of the Board of Advisors of Photon. External Advisor at Bain & Company. Visiting Senior Fellow at LSE Health. Former SVP Healthcare Services at Walgreens Boots Alliance.

Founder and CEO of Lemonaid Health, led the company to a $400 million acquisition by 23andMe. Johnson's expertise extends to securing over $60 million in funding and forging strategic partnerships, such as with Walgreens Boots Alliance in the UK. P

CEO of CorePlus Servicios Clinicos y Patologicos, LLC an anatomic clinical laboratory. Head of Syndeo, LLC a healthcare IT software development enterprise. Both focus on development and implementation of digital pathology and AI solutions.

Dr. Low is a Clinical Associate Professor in the Department of Family & Community Medicine at the University of British Columbia, fulltime practicing family physician in Vancouver and an executive health physician at Mayo Clinic in Arizona.

Debbie Lin focuses on strategic partnerships and venture capital within precision oncology and life sciences, including key roles at Caris Life Sciences and T.Rx Capital. Her expertise extends to academia as a lecturer at UCLA Anderson School of Management and advisory board positions driving growth and innovation in the healthcare sector.

Dr. Tabibiazar is experienced in healthcare and biopharma industries, including venture capital pharmaceuticals and diagnostics. Chair at SalioGen Therapeutics and previous CEO of Aravive Biologics, Practicing cardiologist at Stanford University and trained physician scientist at Harvard Medical School.

Former COO of Exact Sciences (Nasdaq: EXAAS) and Senior Human Resources professional with extensive experience in high-growth companies ranging from start-ups to large multisite corporations.

Professor at the Department of Physics and Engineering Physics at Stevens Institute of Technology, USA. Co-founder of Balter Medical. Developer and specialist in Optical Transfer Diagnosis technology inspired by his published work for NASA and other space agencies.

Dr. Pasquali is a dermatologist and specialist in skin cancer. Former president of the International Society of Tele-dermatology and Chairman of the International Affairs Committee of the American Academy of Dermatology.

Xavier Yon is an experienced healthcare executive with an extensive background in dermatology, including 17 years as Chief Executive Officer of Galderma.